|
|
|
|
|
by wiredearp
2344 days ago
|
|
Ginkgo's CEO explains in some interview [1] how they seek to become co-owners in the companies they involve with since apparently they are well funded for now. "You’re a big company, and you have an idea for what you’d like a cell to do. You come to us, and we agree on the spec. We program the cell to do it. We give you that cell app. That’s our product. It’s essentially an intellectual-property license. We’ve written a piece of custom software for you, except it’s a custom genome inside a cell. You then take that back and build a business around it. The key is: I need to get a piece of that. It could be a royalty or - we just announced a partnership with Y Combinator - we can take equity in companies that are building on top of our platform. We want to make it so that everybody uses our platform to program cells. It’s much cheaper than it’s been historically. You want to start a biotech company? You’ve got to build a lab. You’ve got to get equipment. You’ve got to get all the lab materials. All these things are an enormous upfront expense, and it really limits innovation. So what we’re saying to the Y Combinator companies is: Just use our platform. We’ve already built all that. We have that huge fixed cost, and you get a low marginal cost. And I will program that cell for you in exchange for a chunk of your company. That’s the deal." [1] https://www.bloomberg.com/news/features/2019-11-06/ginkgo-bi... |
|
Wow.